Tirzepatide
$Approved pharmaceutical dual GIP/GLP-1 therapy
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with additional label expansion depending on current product status. It is a prescription drug, not a research peptide.
The evidence base is strong and comes from large SURPASS and SURMOUNT programs. Its long half-life means side effects, dose escalation, missed doses, and washout periods unfold more slowly than people may expect.
Track A1c, weight, waist, blood pressure, lipids, renal function during vomiting or dehydration, gallbladder symptoms, pancreatitis symptoms, lean mass, and oral-contraceptive counseling during initiation and escalation.
Classification details
- Tirzepatide (Zepbound) received FDA approval for obstructive sleep apnea in December 2024, the first medication ever approved for OSA.
- 2025 real-world MASLD/MASH data (ACG 2025) show favorable CV and renal outcomes vs semaglutide in liver-disease populations.
- Tirzepatide is a synthetic 39-amino acid peptide developed by Eli Lilly.
- It is a first-in-class “twincretin,” acting as a dual agonist for both GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors.
- It was FDA-approved in 2022 for Type 2 Diabetes and in 2023 for chronic weight management.
- Tirzepatide is an approved dual GIP/GLP-1 receptor agonist, not just a GLP-1. Product identity, salt/form, device, and indication determine appropriate interpretation.
Tirzepatide is unique because it mimics two endogenous metabolic hormones, creating a synergistic effect on weight and glucose:
- GIP Receptor Agonism: This is the distinguishing arm of Tirzepatide. GIP improves insulin sensitivity and, crucially, acts on the brain to buffer the nausea often caused by GLP-1. It also promotes healthier lipid metabolism in adipose tissue.
- GLP-1 Receptor Agonism: It slows gastric emptying (the “fullness” effect) and signals the brain’s satiety centers to reduce food cravings and “food noise.” Pancreatic Regulation: It stimulates insulin secretion only when blood glucose is high and suppresses glucagon secretion, leading to stabilized blood sugar levels.
- Neuro-Metabolic Signaling: It re-sensitizes the body to its own metabolic signals, making it easier for the body to utilize stored fat for energy.
- It combines GIP and GLP-1 receptor activity to improve glucose regulation, satiety, and weight loss. Delayed gastric emptying is clinically relevant, especially during initiation and escalation.